Conference 2026

.

 

PIPA Conference 2026

The 2026 PIPA Conference was held at the Denham Grove Hotel on 9th & 10th September.

Once again, we offered a dynamic and topical conference programme with many opportunities to network and discuss ideas with colleagues across the industry. We would like to thank our speakers, exhibitors and delegates for attending and making the event a great success.

The full conference programme can be viewed below. For those of you who attended the event, you should be able to see a second copy of the programme for the day(s) you attended with the presentations linked in. If you are unable to see this, then please contact us via pipa@pipaonline.org.

We look forward to welcoming you to the 2027 PIPA conference. Further details will be shared shortly

Conference Programme 2026

Wednesday 9th September – Pharmacovigilance

08:30 Arrival and welcome refreshments
09:00 Conference opening
Chris Isaacs, PIPA President 
09:15 Fireside Discussion: Patient Advocacy in Drug Development
Naomi Litchfield, Director, Patient Advocacy, Bionical Emas & Steve Clark, Patient Engagement Consultant
In this session, Naomi and Steve will:

  • Discuss best practices for patient group engagement
  • Provide examples of patient group perspectives on risk
  • Explore how co-creation with patient groups can impact patient experience
09:45 Panel Discussion: Reimagining aRMMs: Putting Patients at the Centre of Risk Communication
Chair:
Pav Rishiraj, Head of Pharmacovigilance, Celltrion Healthcare
Panellists:
Dr Kathryn Ord, Expert Benefit-Risk Evaluation Assessor, Safety and Surveillance Team, MHRA;
Dr Saad Shakir, Consultant Pharmacovigilance Physician and Pharmacoepidemiologist, ADROITVIGILANCE;
Naomi Litchfield, Director, Patient Advocacy, Bionical Emas;
Steve Clark, Patient Engagement Consultant;
Claire Thomas –
Head of Medicines Optimisation and Welsh Analytical Prescribing Support Unit, AWTTC;
Dianne Burnett – Director, Welsh Medicines Advice Service;
While additional Risk Minimisation Measures (aRMMs) play a vital role in patient safety, they often prioritise regulatory compliance over patient understanding. This panel will explore how we can create more effective, patient-centred materials through digital innovation, meaningful patient involvement, improved accessibility, and greater collaboration to overcome barriers to change.
Find out more about this session
10:45 Exhibition & Tea / Coffee
11:15 Round Table Discussion: The Practical Use of AI Tools in PV and Potential Implications for Inspections

Chair: Indy Ahluwalia, Eliquent
Panellists: Nicole Baker, Biologit; James Whitehead, Egetis; Rory Littlebury, GSK; Abidali Fazal

AI is now working its way into everyday pharmacovigilance but where is it genuinely delivering and where does it fall short? This hour-long round table brings together technology, biotech and big pharma perspectives for a candid look at what’s ready for real use, what “validation” means for AI and how to stay inspection-ready.

12:15 Inspection Readiness: How to Achieve a Positive Inspections Outcome

Stephanie Martin, SMPV Limited

This session aims to clarify inspections and help attendees feel more prepared for future regulatory interactions. By walking through the key steps, before, during, and after an inspection, we look at how daily actions, clear narratives, and knowing how the system works shape inspection results. The session builds confidence, reduces uncertainty, and supports a shared understanding of how positive inspection outcomes are achieved in practice.

13:00 Lunch & Exhibition
14:00 The MHRA / Health Canada Joint Inspection Pilot

Claire Longman, Innovation and Compliance Team, MHRA

The audience will be provided with a summary of the MHRA/Health Canada Joint Inspection Pilot Programme, including the background for the initiative, the purpose, current status and future plans. Foreseen benefits of the pilot will be shared as well as feedback which has been received from those who have been inspected as part of the pilot programme.

14:30 Panel Discussion: the QPPV Office: Maintaining Oversight and How to Have Influence

Chair: Louise Woodward, Roche
Panellists: Elspeth McIntosh, Castle PV Ltd; Deborah Robinson, Jazz Pharmaceuticals; Malgorzata Knurowska, J&J Innovative Medicine

Being a QPPV is more than just a tick-box compliance role.  This engaging, and interactive, panel session on QPPV Oversight and Influence brings experienced QPPVs together to discuss what QPPV oversight means to them and how they achieve it, what happens when issues are identified, how we can build influence to drive real change, and how the QPPV role might evolve in our fast changing landscape.

Find out more about this session

15:30 Exhibition & Tea / Coffee
16:00 PV in Early Access: Designing Systems that Protect Without Over-Engineering

Beata Kolon, PV-Forward, Bionical Emas

Early Access Programmes (EAPs) place the patient at the centre, offering treatment pathways for individuals facing rare or life‑threatening conditions. Because their purpose is compassionate access rather than hypothesis‑driven research, EAPs differ fundamentally in both objective and design from investigational clinical trials.

The Challenge: Designing safety collection in this environment requires balancing elements of Clinical Trial and Post‑Marketing practice while respecting the ethos of Early Access. Faced with regulatory ambiguity and heterogeneous expectations, PV teams often respond by over‑engineering systems to ensure compliance. This can increase burden for healthcare professionals, generate low‑value data, and obscure meaningful safety insights. The central question is how to build proportionate, compliant safety collection without losing sight of what matters.

The Solution: This session offers practical insight for PV leaders working across the product lifecycle. It outlines how to shift from defensive engineering to proportionate, risk‑based design anchored in the principles that define Early Access.

Aims & Takeaways: Participants will gain a clearer understanding of what makes Early Access safety collection distinct, and why over‑engineered systems can undermine both compliance and patient protection. The session will build awareness of proportionate, risk‑based approaches suited to EAPs and highlight the principles that help PV teams navigate regulatory ambiguity without creating unnecessary operational burden. Attendees will leave with a grounded sense of how lean, fit‑for‑purpose EAP workflows can be shaped — and where to focus their attention when entering this space.

Find out more about this session

16:30 New Device Regulations: How to Practically Implement in the PV Department and Avoid Pitfalls

Jess Auton, B Braun Medical Ltd

The medical devices post market surveillance regulation came into play in June 2025 and this affects how vigilance of combination devices, where the PMOA is a medical device, are reported to the MHRA. This regulation tightens post market surveillance but there are subtle differences to that in Europe.

17:00 Bridging Species From Paws to Patients: Lessons, Similarities, and Differences in Human and Animal Pharmacovigilance

Janine Gavin, VIGINEXT

Pharmacovigilance is often perceived as an exclusively human medicine discipline, yet the principles underpinning drug safety monitoring apply equally across species. This session takes delegates on a comparative journey through human and veterinary pharmacovigilance, exploring the regulatory frameworks, reporting obligations, and benefit-risk methodologies that both sectors share, while highlighting the unique challenges that make veterinary pharmacovigilance a discipline in its own right. From monitoring drug safety across dozens of species, to food chain safety and antimicrobial resistance, this session reveals how the two worlds are more connected than many realise — and why bridging them under the One Health framework is not just valuable, but essential.

17:30 End of PV day
19:00 Drinks reception, evening meal and networking event

 

Thursday 10th September – Medical Information

08:30 Arrival and welcome refreshments
09:00 Conference opening
Chris Isaacs, PIPA President 
09:15 Unlock Your Ability to Engage With a Larger HCP Community Through Structured Data

Tara Protheroe, Sr Product Manager, Datapharm

Every day, healthcare professionals across the UK turn to emc as part of their prescribing journey, generating more than 2 million sessions a month across 13,000+ approved medicines.

In this talk, Tara Protheroe, Senior Product Manager at Datapharm, shares what that vantage point reveals: fresh insights into how HCPs actually engage with medicines information in 2026, how often they return, and how their behaviour is changing – including the growing influence of AI.

She’ll also explore how structured data is enabling safety-critical information, including aRMMs, to move closer to the point of care through digital dissemination and partnerships.

Attendees will leave with a clearer picture of their audience, and practical ways to make their own medicines information work harder.

Find out more about this session

09:45 Panel Discussion: AI in First-Line Medical Information: Are We Ready for the Future?

Chair: Laura Avanzo Leeke, PIPA
Panellists: Diogo Silva, Eversana; Hannah Hunter, ProPharma Group;  Jenny Reid-Young, Inizio; Ghiesla Nel, PPD ThermoFisher; Stavros Tsompanidis, Nexentria

Join this interactive panel discussion at the PIPA Conference as industry leaders, Medical Information experts, technology innovators and service providers explore how artificial intelligence is transforming first-line Medical Information.

The panel will discuss real-world AI applications, the benefits already being realised, and the challenges that remain around scientific accuracy, compliance, governance and audit readiness. Together, we’ll examine how AI is reshaping MI roles, skills and customer interactions, and debate what the future of Medical Information could look like over the next five years.

Will AI soon handle most routine enquiries, with MI professionals acting primarily as scientific reviewers and consultants? Expect diverse perspectives, lively debate and practical insights for organisations at every stage of their AI journey.

Whether you’re exploring AI for the first time or already implementing solutions, this session will provide valuable lessons, thought-provoking discussion and opportunities to engage with leading experts in the field.

Find out more about this session

Find out more about this session

10:45 Exhibition & Tea / Coffee
11:15 Interactive Session: AI Tools in Medical Information

Stefan Sassmann, Global Medical Information Manager, Recordati

How can Medical Information professionals make the most of AI while avoiding common pitfalls? This session will explore practical AI applications in Medical Information, including information retrieval, literature searching, data visualisation, and content generation. Through demonstrations and real-world examples, attendees will see how general AI tools compare with specialised Medical Information solutions, where each can add value, and what limitations must be considered. Key topics such as compliance, copyright, transparency, and human oversight will also be discussed, providing a balanced perspective on the opportunities and challenges of AI in Medical Information.

Find out more about this session

12:00 AI in MI Workshop

Michelle Bridenbaker, Vice President Medical Information Leaders in Europe, Global Head of Medical Excellence & Communications, Recordati

In this session we will explore how we can concretely implement AI in our teams by participating in this interactive workshop session to give you the time to think and explore what is possible!

13:00 Lunch & Exhibition
14:00 ABPI Code Update

Jayne Packham, Jayne Packham Consultancy

We’ll explore the latest trends in the ABPI Code of Practice, including information claims, social media and opportunities for AI.

15:00 Unlocking Potential: Leveraging Medical Information Insights for Cross-Functional Impact

Tea Meneghetti, Medical Insights Partner, Astellas

In this session, we’ll explore how Medical Information can and should feed into overall Medical strategy, leveraging its incredible positioning and value across any organisation, and why it should be a primary asset to Medical Affairs initiatives.

15:45 Exhibition & Tea / Coffee
16:15 Panel Discussion: Building Effective Bridges Between Global and Local Medical Information Functions, While Strengthening Cross-Departmental Collaboration

Chair: Simran Marway, Medical Information Manager UK / IE, Sanofi
Panellists: Amber Macnaughton, Ipsen; Francisco Gomez, Associate Director Medical Information, Incyte; Sebastian Rodriguez, Director, ACE Region Lead, Global Medical Information, Gilead Sciences Europe Ltd; Atilla Altinok, Senior Manager, Global Medical Information, Amgen

During this panel discussion, we will share practical approaches to aligning global-local collaboration, enabling knowledge sharing, strengthening cross-departmental partnerships, and positioning MI as a strategic asset. Ideal for MI professionals seeking to build stronger internal partnerships and elevate MI’s strategic influence.

Find out more about this session

17:15 Conference close